Clinical Trial Search

Primary: Number of Patient Participants Retained in the Intervention (Out of All of Those Enrolled), as Measured by Completion to All Study Treatment Visits. — 17 Participants

Primary: Number of Participants With All Treatment-emergent Adverse Events (TEAEs), Serious and Non-serious Treatment-emergent Adverse Events and Serious and Non-serious…

Primary: Parts 1, 2, and 3: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 216; 221; 93; 24 Participants

Primary: Acute Radiation Effects (Less Than 90 Days Post Treatment) — 0 Participants

Primary: Incontinence Episodes — -2.25; -0.14 number of incontinencies

Primary: Percentage of Fat-free Mass — 49.6; 50.3; 50.5; 52.5 percentage of fat-free mass — p=0.013

Primary: Percentage of Participants With a Continuous Smoking Abstinence Rate — 0 percentage of participants

Primary: Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) Assay — 120.5; 104.3; 137.7; 97.3 titer

Primary: Change in Public Speaking Anxiety — 6.5; 6.6; 6.2; 6.3 units on a scale

Primary: Area Under the Curve to Infinity (AUCinf) of Apraglutide — 4481; 3744 h*ng/mL

Primary: Heavy Drinking Days Per Week Change — -1.76; -2.3 Mean heavy drinking days per week

Primary: Time to Seroconversion After One Vaccination Using Bavarian Nordic's (BN) Enzyme Linked Immunosorbent Assay (ELISA) in the Intent-to-Treat (ITT) Population — 14; 14 days

Primary: Number of Patients With Adverse Events (AE), Graded According to Common Terminology Criteria for Adverse Events Version 5.0 — 0 Participants

Primary: Real Time and Single Breath End-tidal (EtO2) Measurements — 34; 63; 92; 58.5 percentage of end-tidal oxygen

Primary: Endotoxin — 14.44; 12.97; 12.25; 17.65 EU/mL